A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis
Latest Information Update: 12 Jan 2024
At a glance
- Drugs Bomedemstat (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Imago BioSciences
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2022 According to an Imago BioSciences media release, data from the study were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
- 12 Dec 2022 Results published in the Media Release